Financial Ratios Acurx Pharmaceuticals, Inc.

Equities

ACXP

US00510M2035

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2026-05-08 pm EDT			5-day change	1st Jan Change
2.090 ^USD	-1.42%		-3.24%	-16.06%

May. 04	Acurx Pharmaceuticals, Inc. Presents Scientific Poster on DNA Pol IIIC Inhibitors' Microbiome Evaluation at ESCMID Global	CI
Apr. 26	Acurx Pharmaceuticals, Inc., Adiso Therapeutics, Inc., Summit Therapeutics Inc., Finch Therapeutics Group, Inc. and Astrazeneca plc Announces Clostridium Difficile Infections Clinical Trial Updates	CI

7e71332f3f7b32bb8518.k_3AswWpKyw6krqhvmriodfoS7v9q4syh6WrkZIM354.9NDz5zHjeGlZwcjo9D6g1-LRAuKxyOFWvvft6PpYj-nYmLrcXcx5Z1yrig

Published financial data: ACURX PHARMACEUTICALS, INC.

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: December	2021	2022	2023	2024	2025
Selling General & Admin Expenses, Total	10.78M	7.34M	8.53M	8.7M	6.26M
R&D Expenses	2.03M	4.75M	6.04M	5.4M	1.83M
Other Operating Expenses, Total	12.81M	12.09M	14.58M	14.1M	8.09M
Operating Income	-12.81M	-12.09M	-14.58M	-14.1M	-8.09M
Interest And Investment Income	-	-	-	-	125K
Net Interest Expenses	-	-	-	-	125K
EBT, Excl. Unusual Items	-12.81M	-12.09M	-14.58M	-14.1M	-7.97M
Other Unusual Items	66.5K	-	-	-	-
EBT, Incl. Unusual Items	-12.75M	-12.09M	-14.58M	-14.1M	-7.97M
Earnings From Continuing Operations	-12.75M	-12.09M	-14.58M	-14.1M	-7.97M
Net Income to Company	-12.75M	-12.09M	-14.58M	-14.1M	-7.97M
Net Income - (IS)	-12.75M	-12.09M	-14.58M	-14.1M	-7.97M
Net Income to Common Incl Extra Items	-12.75M	-12.09M	-14.58M	-14.1M	-7.97M
Net Income to Common Excl. Extra Items	-12.75M	-12.09M	-14.58M	-14.1M	-7.97M
Per Share Items
Net EPS - Basic	-29.87	-22.36	-23.01	-17.45	-5.32
Basic EPS - Continuing Operations	-29.87	-22.36	-23.01	-17.45	-5.32
Basic Weighted Average Shares Outstanding	427K	541K	634K	808K	1.5M
Net EPS - Diluted	-29.87	-22.4	-23.01	-17.45	-5.32
Diluted EPS - Continuing Operations	-29.87	-22.4	-23.01	-17.45	-5.32
Diluted Weighted Average Shares Outstanding	427K	541K	634K	808K	1.5M
Normalized Basic EPS	-18.77	-13.98	-14.38	-10.91	-3.32
Normalized Diluted EPS	-18.77	-13.98	-14.38	-10.91	-3.32
Supplemental Items
EBITA	-12.81M	-12.09M	-14.58M	-14.1M	-8.09M
EBIT	-12.81M	-12.09M	-14.58M	-14.1M	-8.09M
Normalized Net Income	-8.01M	-7.56M	-9.11M	-8.81M	-4.98M
Supplemental Operating Expense Items
General and Administrative Expenses	10.78M	7.34M	8.53M	8.7M	6.26M
Research And Development Expense From Footnotes	2.03M	4.75M	6.04M	5.4M	1.83M
Stock-Based Comp., R&D Exp. (Total)	21.6K	-	-	-	-
Stock-Based Comp., G&A Exp. (Total)	5.76M	3.3M	3.77M	3.44M	322K
Stock-Based Comp., Other (Total)	1.87M	-	-	-	1.25M
Total Stock-Based Compensation	7.66M	3.3M	3.77M	3.44M	1.57M

Fiscal Period: December	2021	2022	2023	2024	2025
Assets
Cash And Equivalents	12.96M	9.11M	7.47M	3.71M	7.56M
Total Cash And Short Term Investments	12.96M	9.11M	7.47M	3.71M	7.56M
Other Receivables	-	-	129K	51.13K	48.42K
Total Receivables	-	-	129K	51.13K	48.42K
Prepaid Expenses	295K	265K	106K	100K	85.02K
Total Current Assets	13.25M	9.38M	7.71M	3.86M	7.69M
Total Assets	13.25M	9.38M	7.71M	3.86M	7.69M
Liabilities
Accounts Payable, Total	63.37K	29.54K	3.81K	4.79K	6.8K
Accrued Expenses, Total	781K	2.03M	3.04M	3.24M	2.41M
Current Portion of Long-Term Debt	-	-	-	-	-
Other Current Liabilities	-	-	-	-	-
Total Current Liabilities	844K	2.06M	3.04M	3.24M	2.42M
Long-Term Debt	-	-	-	-	-
Total Liabilities	844K	2.06M	3.04M	3.24M	2.42M
Common Stock, Total	10.22K	11.63K	14.47K	17.03K	2.35K
Additional Paid In Capital	38.95M	45.94M	57.87M	67.92M	80.55M
Retained Earnings	-26.55M	-38.64M	-53.22M	-67.32M	-75.29M
Total Common Equity	12.41M	7.32M	4.67M	615K	5.27M
Total Equity	12.41M	7.32M	4.67M	615K	5.27M
Total Liabilities And Equity	13.25M	9.38M	7.71M	3.86M	7.69M
Supplemental Items
ECS Total Shares Outstanding on Filing Date	512K	582K	788K	1.1M	2.86M
ECS Total Common Shares Outstanding	511K	581K	723K	852K	2.35M
Book Value / Share	24.3	12.58	6.45	0.72	2.24
Tangible Book Value	12.41M	7.32M	4.67M	615K	5.27M
Tangible Book Value Per Share	24.3	12.58	6.45	0.72	2.24
Total Debt	0	0	0	0	0
Net Debt	-12.96M	-9.11M	-7.47M	-3.71M	-7.56M
Account Code - Inventory Valuation	3	3	3	3	3
Full Time Employees	3	4	4	4	4
Part Time Employees	-	-	-	-	-

Fiscal Period: December	2021	2022	2023	2024	2025
Net Income	-12.75M	-12.09M	-14.58M	-14.1M	-7.97M
Stock-Based Compensation (CF)	6.07M	2.87M	3.77M	3.44M	1.57M
Other Operating Activities, Total	1.52M	431K	-	-	-
Change In Accounts Payable	388K	1.22M	981K	200K	-409K
Change in Other Net Operating Assets	-247K	30.35K	30.02K	83.68K	17.82K
Cash from Operations	-5.01M	-7.54M	-9.8M	-10.38M	-6.79M
Long-Term Debt Issued, Total	-	-	-	-	-
Total Debt Issued	-	-	-	-	-
Issuance of Common Stock	14.8M	3.7M	8.16M	6.62M	10.78M
Other Financing Activities, Total	-	-	-	-	-146K
Cash from Financing	14.8M	3.7M	8.16M	6.62M	10.64M
Net Change in Cash	9.78M	-3.85M	-1.64M	-3.77M	3.85M
Supplemental Items
Levered Free Cash Flow	-208K	-3.01M	-4.33M	-5.09M	-4.29M
Unlevered Free Cash Flow	-208K	-3.01M	-4.33M	-5.09M	-4.29M
Change In Net Working Capital	-141K	-1.25M	-1.01M	-284K	804K
Net Debt Issued / Repaid	-	-	-	-	-

Fiscal Period: December	2021	2022	2023	2024	2025
Profitability
Return on Assets	-97.21	-66.79	-106.65	-152.41	-87.59
Return on Total Capital	-105.53	-76.63	-152.08	-333.77	-171.91
Return On Equity %	-168.71	-122.61	-243.33	-534.03	-270.8
Return on Common Equity	-168.71	-122.61	-243.33	-534.03	-270.8
Short Term Liquidity
Current Ratio	15.71	4.55	2.53	1.19	3.18
Quick Ratio	15.36	4.42	2.5	1.16	3.14
Operating Cash Flow to Current Liabilities	-5.94	-3.66	-3.22	-3.2	-2.8
Long Term Solvency
Total Debt/Equity	-	-	-	-	-
Total Debt / Total Capital	-	-	-	-	-
LT Debt/Equity	-	-	-	-	-
Long-Term Debt / Total Capital	-	-	-	-	-
Total Liabilities / Total Assets	6.37	21.99	39.47	84.06	31.48
Growth Over Prior Year
EBITA, 1 Yr. Growth %	178.57	-5.63	20.55	-3.26	-42.7
EBIT, 1 Yr. Growth %	178.57	-5.63	20.55	-3.26	-42.7
Earnings From Cont. Operations, 1 Yr. Growth %	177.12	-5.14	20.55	-3.26	-43.51
Net Income, 1 Yr. Growth %	177.12	-5.14	20.55	-3.26	-43.51
Normalized Net Income, 1 Yr. Growth %	178.57	-5.63	20.55	-3.26	-43.51
Diluted EPS Before Extra, 1 Yr. Growth %	100.99	-25	2.9	-24.16	-69.54
Total Assets, 1 Yr. Growth %	311.11	-29.25	-17.78	-49.96	99.32
Tangible Book Value, 1 Yr. Growth %	359.37	-41.06	-36.2	-86.82	756.51
Common Equity, 1 Yr. Growth %	359.37	-41.06	-36.2	-86.82	756.51
Cash From Operations, 1 Yr. Growth %	49.59	50.43	29.95	5.94	-34.63
Levered Free Cash Flow, 1 Yr. Growth %	-89.99	1.34K	44.11	17.55	-15.97
Unlevered Free Cash Flow, 1 Yr. Growth %	-89.99	1.34K	44.11	17.55	-15.97
Compound Annual Growth Rate Over Two Years
EBITA, 2 Yr. CAGR %	46.98	62.14	6.66	7.99	-25.5
EBIT, 2 Yr. CAGR %	46.98	62.14	6.66	7.99	-25.5
Earnings From Cont. Operations, 2 Yr. CAGR %	46.6	62.14	6.94	7.99	-26.08
Net Income, 2 Yr. CAGR %	46.6	62.14	6.94	7.99	-26.08
Normalized Net Income, 2 Yr. CAGR %	46.98	62.14	6.66	7.99	-26.08
Diluted EPS Before Extra, 2 Yr. CAGR %	9.38	22.77	-12.23	-11.66	-51.94
Total Assets, 2 Yr. CAGR %	128.82	70.54	-23.73	-35.86	-0.13
Tangible Book Value, 2 Yr. CAGR %	289.06	64.55	-38.68	-71	6.25
Common Equity, 2 Yr. CAGR %	289.06	64.55	-38.68	-71	6.25
Cash From Operations, 2 Yr. CAGR %	12.16	50.01	39.81	17.33	-16.78
Levered Free Cash Flow, 2 Yr. CAGR %	-	20.2	356.07	30.15	-0.49
Unlevered Free Cash Flow, 2 Yr. CAGR %	-	20.2	356.07	30.15	-0.49
Compound Annual Growth Rate Over Three Years
EBITA, 3 Yr. CAGR %	-	26.8	46.88	3.25	-12.53
EBIT, 3 Yr. CAGR %	-	26.8	46.88	3.25	-12.53
Earnings From Cont. Operations, 3 Yr. CAGR %	-	26.8	46.88	3.43	-12.99
Net Income, 3 Yr. CAGR %	-	26.8	46.88	3.43	-12.99
Normalized Net Income, 3 Yr. CAGR %	-	26.8	46.88	3.25	-12.99
Diluted EPS Before Extra, 3 Yr. CAGR %	-	-3.55	15.69	-16.4	-38.05
Total Assets, 3 Yr. CAGR %	-	54.73	33.72	-33.73	-6.4
Tangible Book Value, 3 Yr. CAGR %	-	107.41	19.99	-63.27	-10.36
Common Equity, 3 Yr. CAGR %	-	107.41	19.99	-63.27	-10.36
Cash From Operations, 3 Yr. CAGR %	-	23.69	43	27.47	-3.45
Levered Free Cash Flow, 3 Yr. CAGR %	-	-	27.7	190.24	12.58
Unlevered Free Cash Flow, 3 Yr. CAGR %	-	-	27.7	190.24	12.58
Compound Annual Growth Rate Over Five Years
EBITA, 5 Yr. CAGR %	-	-	-	18.91	11.96
EBIT, 5 Yr. CAGR %	-	-	-	18.91	11.96
Earnings From Cont. Operations, 5 Yr. CAGR %	-	-	-	18.91	11.61
Net Income, 5 Yr. CAGR %	-	-	-	18.91	11.61
Normalized Net Income, 5 Yr. CAGR %	-	-	-	18.91	11.61
Diluted EPS Before Extra, 5 Yr. CAGR %	-	-	-	-6.91	-18.59
Total Assets, 5 Yr. CAGR %	-	-	-	8.79	18.99
Tangible Book Value, 5 Yr. CAGR %	-	-	-	-5.58	14.29
Common Equity, 5 Yr. CAGR %	-	-	-	-5.58	14.29
Cash From Operations, 5 Yr. CAGR %	-	-	-	21.11	15.16
Levered Free Cash Flow, 5 Yr. CAGR %	-	-	-	-	15.57
Unlevered Free Cash Flow, 5 Yr. CAGR %	-	-	-	-	15.57